1 |
Canever JB, Soares ES, de Avelar NCP, Cimarosti HI. Targeting α-synuclein post-translational modifications in Parkinson's disease. Behav Brain Res 2023;439:114204. [PMID: 36372243 DOI: 10.1016/j.bbr.2022.114204] [Reference Citation Analysis]
|
2 |
Cheng Y, Tong Q, Yuan Y, Song X, Jiang W, Wang Y, Li W, Li Y, Zhang K. α-Synuclein induces prodromal symptoms of Parkinson's disease via activating TLR2/MyD88/NF-κB pathway in Schwann cells of vagus nerve in a rat model. J Neuroinflammation 2023;20:36. [PMID: 36788559 DOI: 10.1186/s12974-023-02720-1] [Reference Citation Analysis]
|
3 |
Bartl M, Dakna M, Schade S, Otte B, Wicke T, Lang E, Starke M, Ebentheuer J, Weber S, Toischer K, Schnelle M, Sixel-Döring F, Trenkwalder C, Mollenhauer B. Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease. Mov Disord 2023;38:68-81. [PMID: 36267007 DOI: 10.1002/mds.29257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
4 |
Channer B, Matt SM, Nickoloff-Bybel EA, Pappa V, Agarwal Y, Wickman J, Gaskill PJ. Dopamine, Immunity, and Disease. Pharmacol Rev 2023;75:62-158. [PMID: 36757901 DOI: 10.1124/pharmrev.122.000618] [Reference Citation Analysis]
|
5 |
Forloni G, La Vitola P, Balducci C. Oligomeropathies, inflammation and prion protein binding. Front Neurosci 2022;16:822420. [DOI: 10.3389/fnins.2022.822420] [Reference Citation Analysis]
|
6 |
Chatterjee K, Choudhury S, Banerjee R, Siddique U, Sarkar S, Roy A, Chatterjee CS, Ghosal A, Basu P, Kumar H. Is peripheral alpha synuclein a marker for gait velocity in Parkinson's disease? Neurosci Lett 2022;786:136819. [PMID: 35905887 DOI: 10.1016/j.neulet.2022.136819] [Reference Citation Analysis]
|